metoclopramide has been researched along with Breast Cancer in 38 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of PONV after breast cancer surgery in Japanese patients." | 9.13 | Comparison of propofol, droperidol, and metoclopramide for prophylaxis of postoperative nausea and vomiting after breast cancer surgery: a prospective, randomized, double-blind, placebo-controlled study in Japanese patients. ( Fujii, Y; Itakura, M, 2008) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 9.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 9.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 9.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 9.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "For women with breast cancer who are being treated with cyclophosphamide, methotrexate, and fluorouracil, the efficacy of dexamethasone and metoclopramide in controlling nausea and vomiting equaled or exceeded that of ondansetron." | 9.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| " cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), 25 women with stage II breast cancer were entered into this study." | 9.06 | Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. ( Giannarelli, D; Marolla, P; Nardi, M; Pinnaró, P; Pollera, CF; Terzoli, E, 1989) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 9.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 9.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 9.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "A randomized trial was performed comparing the antiemetic efficacy of methylprednisolone (MPN) and metoclopramide (MCP) in 60 breast cancer patients eligible for outpatient adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-FU (CMF)." | 9.05 | The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial. ( Bruzzi, P; Campora, E; Chiara, S; Rosso, R; Scarsi, P, 1985) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 7.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 7.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 6.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| " Patients received an intravenous dose of 16 mg dexamethasone with either 8 mg ondansetron or 60 mg metoclopramide before chemotherapy, followed by oral dosing with 8 mg ondansetron or 20 mg metoclopramide 3 times daily for 5 days." | 6.67 | Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. ( Cassidy, J; Coleman, R; Hunter, E; Kaye, S; Kerr, D; Khanna, S; McQuade, B; Smyth, J; Soukop, M; Stewart, A, 1992) |
| " The MCP and DXM dosage were: 2 X 2 mg/kg and 2 X 0." | 5.27 | High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer. ( Gerra, C; Gez, E; Goodman, S; Isacson, R; Sulkes, A, 1986) |
| "The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of PONV after breast cancer surgery in Japanese patients." | 5.13 | Comparison of propofol, droperidol, and metoclopramide for prophylaxis of postoperative nausea and vomiting after breast cancer surgery: a prospective, randomized, double-blind, placebo-controlled study in Japanese patients. ( Fujii, Y; Itakura, M, 2008) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 5.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 5.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 5.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 5.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "For women with breast cancer who are being treated with cyclophosphamide, methotrexate, and fluorouracil, the efficacy of dexamethasone and metoclopramide in controlling nausea and vomiting equaled or exceeded that of ondansetron." | 5.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 5.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "40 patients with metastatic breast cancer, under treatment with epirubicin (greater than 50 mg/m2) and cyclophosphamide (greater than 500 mg/m2), had an antiemetic therapy with Ondansetron 3 x 8 mg day, for a maximum of 10 cycles." | 5.06 | [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron]. ( Adler, M; Albrecht, U; Jaenicke, F; Marschner, NW; Nagel, GA, 1990) |
| " cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), 25 women with stage II breast cancer were entered into this study." | 5.06 | Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. ( Giannarelli, D; Marolla, P; Nardi, M; Pinnaró, P; Pollera, CF; Terzoli, E, 1989) |
| "Nineteen women receiving their first cycle of adjuvant chemotherapy for early breast cancer were randomized between two antiemetic drugs: methylprednisolone (MPN) 125mg and metoclopramide (MCP) 20mg, both given by intravenous push as a single dose." | 5.06 | Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study. ( Biran, S; Cass, Y; Gera, C; Gez, E; Nathan, S; Ochayon, L; Rubello, E; Sulkes, A, 1989) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 5.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 5.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "In more than 70% of patients undergoing surgery for breast cancer with histologically positive lymph nodes, precautional therapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) causes nausea and vomiting." | 5.05 | Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; Minotti, V; Roila, F; Tonato, M, 1985) |
| "A randomized trial was performed comparing the antiemetic efficacy of methylprednisolone (MPN) and metoclopramide (MCP) in 60 breast cancer patients eligible for outpatient adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-FU (CMF)." | 5.05 | The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial. ( Bruzzi, P; Campora, E; Chiara, S; Rosso, R; Scarsi, P, 1985) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 3.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "A case of severe metoclopramide-induced akathisia in a breast cancer patient being treated with chemotherapy is presented, eventually culminating in hospital admission." | 3.76 | Severe akathisia as a side effect of metoclopramide. ( Doorduijn, JK; Seynaeve, C; Van Gool, AR, 2010) |
| "A two-stage retrospective audit of the efficacy of antiemetics used with intravenous cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and 5-fluorouracil 600 mg/m2 (CMF) chemotherapy for breast cancer has been performed in a single centre." | 3.70 | An audit of antiemetic use with CMF chemotherapy. ( Brown, RS; Brown, TK; Gaze, MN; Hoare, D, 1998) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 3.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| " She was given 1,700 mg metoclopramide IV for 2 months to prevent nausea and vomiting." | 3.67 | Metoclopramide-induced phantom dyskinesia. ( Glass, JP; Jankovic, J, 1985) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 2.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "56 female patients with breast carcinoma and treated with polychemotherapy: adriamycin, vindesine, ciclophosphamide and 5-fluorouracil were studied, divided in three groups with different antiemetic schedule: group A 40 mg/iv of metoclopramide; group B 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone before beginning chemotherapy; and group C 2 mg/oral of lorazepam, 125 mg/iv methyl-prednisolone and 1 mg/kg/oral of metoclopramide previously to begin chemotherapy; at two and four hours of the first dose, metoclopramide was repeated the same doses (really) three doses each two hours." | 2.67 | [Antiemetic treatments associated with antineoplastic chemotherapy]. ( Guillén Lloveria, G; Mayordomo Cámara, JJ; Sáenz Cusi, A; Sáez Martínez, MJ; Tres Sánchez, A, 1990) |
| " Patients received an intravenous dose of 16 mg dexamethasone with either 8 mg ondansetron or 60 mg metoclopramide before chemotherapy, followed by oral dosing with 8 mg ondansetron or 20 mg metoclopramide 3 times daily for 5 days." | 2.67 | Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. ( Cassidy, J; Coleman, R; Hunter, E; Kaye, S; Kerr, D; Khanna, S; McQuade, B; Smyth, J; Soukop, M; Stewart, A, 1992) |
| "All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study." | 1.39 | Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013) |
| "Prolactin is a suspected promotor of breast cancer cell growth, and it shares pleiotropic immunoregulatory properties." | 1.31 | Elevation of plasma prolactin in patients undergoing autologous blood stem-cell transplantation for breast cancer: is its modulation a step toward posttransplant immunotherapy? ( Bauer, K; Fangl, M; Habertheuer, KH; Hinterberger, W; Hinterberger-Fischer, M; Kier, P; Kittl, E; Ogris, E; Ruckser, R; Schmid, A; Sebesta, C; Selleny, S, 2000) |
| " The MCP and DXM dosage were: 2 X 2 mg/kg and 2 X 0." | 1.27 | High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer. ( Gerra, C; Gez, E; Goodman, S; Isacson, R; Sulkes, A, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (39.47) | 18.7374 |
| 1990's | 16 (42.11) | 18.2507 |
| 2000's | 5 (13.16) | 29.6817 |
| 2010's | 2 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, Y | 2 |
| Itakura, M | 1 |
| Van Gool, AR | 1 |
| Doorduijn, JK | 1 |
| Seynaeve, C | 1 |
| Oddby-Muhrbeck, E | 1 |
| Öbrink, E | 1 |
| Eksborg, S | 1 |
| Rotstein, S | 1 |
| Lönnqvist, PA | 1 |
| Tomono, H | 1 |
| Ito, Y | 1 |
| Watanabe, T | 1 |
| Framarino dei Malatesta, M | 1 |
| Veneziano, M | 1 |
| Fiorelli, C | 1 |
| Bandiera, AF | 1 |
| Yacoub, M | 1 |
| Toccaceli Blasi, MR | 1 |
| Marzetti, L | 1 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Khoo, KS | 1 |
| Levitt, M | 1 |
| Warr, D | 1 |
| Yelle, L | 1 |
| Rayner, HL | 1 |
| Lofters, WS | 1 |
| Perrault, DJ | 1 |
| Wilson, KS | 1 |
| Latreille, J | 1 |
| Potvin, M | 1 |
| Warner, E | 1 |
| Hansen, O | 1 |
| Pfeiffer, P | 1 |
| Madsen, B | 1 |
| Andersen, I | 1 |
| Hansen, B | 1 |
| Mathiesen, B | 1 |
| Barrenetxea, G | 1 |
| Schneider, J | 2 |
| Centeno, MM | 1 |
| Romero, H | 1 |
| de la Rica, M | 1 |
| Rodríguez-Escudero, FJ | 1 |
| Tanaka, H | 1 |
| Toyooka, H | 1 |
| Brown, RS | 1 |
| Brown, TK | 1 |
| Hoare, D | 1 |
| Gaze, MN | 1 |
| Mabro, M | 1 |
| Granisétron, PK | 1 |
| Lachaine, J | 1 |
| Laurier, C | 1 |
| Langleben, A | 1 |
| Vaillant, L | 1 |
| Hinterberger-Fischer, M | 1 |
| Ogris, E | 1 |
| Kier, P | 1 |
| Bauer, K | 1 |
| Kittl, E | 1 |
| Habertheuer, KH | 1 |
| Ruckser, R | 1 |
| Schmid, A | 1 |
| Selleny, S | 1 |
| Fangl, M | 1 |
| Sebesta, C | 1 |
| Hinterberger, W | 1 |
| Bosnjak, SM | 1 |
| Nesković-Konstantinović, ZB | 1 |
| Radulović, SS | 1 |
| Susnjar, S | 1 |
| Mitrovi, LB | 1 |
| Molassiotis, A | 1 |
| Edelstyn, GA | 1 |
| MacRae, KD | 1 |
| MacDonald, FM | 1 |
| Bohnet, HG | 1 |
| Naber, NG | 1 |
| del Pozo, E | 1 |
| Schneider, HP | 1 |
| Panadés Nigorra, G | 1 |
| Soukop, M | 1 |
| McQuade, B | 1 |
| Hunter, E | 1 |
| Stewart, A | 1 |
| Kaye, S | 1 |
| Cassidy, J | 1 |
| Kerr, D | 1 |
| Khanna, S | 1 |
| Smyth, J | 1 |
| Coleman, R | 1 |
| Marschner, N | 1 |
| Marschner, NW | 2 |
| Adler, M | 2 |
| Nagel, GA | 2 |
| Christmann, D | 1 |
| Fenzl, E | 1 |
| Upadhyaya, B | 1 |
| Tres Sánchez, A | 1 |
| Sáez Martínez, MJ | 1 |
| Mayordomo Cámara, JJ | 1 |
| Guillén Lloveria, G | 1 |
| Sáenz Cusi, A | 1 |
| Bonneterre, J | 1 |
| Chevallier, B | 1 |
| Metz, R | 1 |
| Fargeot, P | 1 |
| Pujade-Lauraine, E | 1 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Paes, D | 1 |
| Bons, J | 1 |
| Jaenicke, F | 1 |
| Albrecht, U | 1 |
| Kikuchi, K | 1 |
| Tsuyuki, A | 1 |
| Fujishiro, Y | 1 |
| Utsumi, T | 1 |
| Fujisaki, M | 1 |
| Kurihara, E | 1 |
| Uematsu, M | 1 |
| Pollera, CF | 1 |
| Nardi, M | 1 |
| Marolla, P | 1 |
| Pinnaró, P | 1 |
| Terzoli, E | 1 |
| Giannarelli, D | 1 |
| Gez, E | 3 |
| Sulkes, A | 2 |
| Ochayon, L | 1 |
| Gera, C | 1 |
| Nathan, S | 1 |
| Cass, Y | 1 |
| Rubello, E | 1 |
| Biran, S | 2 |
| Völker, W | 1 |
| Leipert, KP | 1 |
| Gehrlings, H | 1 |
| Stauch, G | 1 |
| von zur Mühlen, A | 1 |
| Roila, F | 3 |
| Tonato, M | 3 |
| Basurto, C | 3 |
| Minotti, V | 3 |
| Ballatori, E | 3 |
| del Favero, A | 2 |
| Warner-Efraty, E | 1 |
| Ben-Yosef, R | 1 |
| Ben-Baruch, N | 1 |
| Yitzhaki, N | 1 |
| Uziely, B | 1 |
| Brufman, G | 1 |
| Goodman, S | 1 |
| Isacson, R | 1 |
| Gerra, C | 1 |
| Campora, E | 1 |
| Chiara, S | 1 |
| Bruzzi, P | 1 |
| Scarsi, P | 1 |
| Rosso, R | 1 |
| Jankovic, J | 1 |
| Glass, JP | 1 |
| Ward, HW | 1 |
1 review available for metoclopramide and Breast Cancer
| Article | Year |
|---|---|
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
23 trials available for metoclopramide and Breast Cancer
| Article | Year |
|---|---|
Comparison of propofol, droperidol, and metoclopramide for prophylaxis of postoperative nausea and vomiting after breast cancer surgery: a prospective, randomized, double-blind, placebo-controlled study in Japanese patients.
Topics: Aged; Antiemetics; Asian People; Breast Neoplasms; Double-Blind Method; Droperidol; Female; Humans; | 2008 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Fem | 1994 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplas | 1996 |
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1996 |
Prevention of nausea and vomiting in female patients undergoing breast surgery: a comparison with granisetron, droperidol, metoclopramide and placebo.
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Droperidol; Female; Granisetron; Humans; | 1998 |
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Drug Therapy, Combination; Female; | 1999 |
High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemoth | 2000 |
A pilot study of the use of progressive muscle relaxation training in the management of post-chemotherapy nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cost | 2000 |
Improvement of life quality in cancer patients undergoing chemotherapy.
Topics: Alopecia; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Clinical Trials as Topic; C | 1979 |
Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Dexamethasone; Drug Tolerance; Female; | 1992 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Im | 1991 |
[Antiemetic treatments associated with antineoplastic chemotherapy].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
[Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dou | 1990 |
Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dex | 1989 |
Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; F | 1989 |
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1988 |
Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1985 |
The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 1985 |
15 other studies available for metoclopramide and Breast Cancer
| Article | Year |
|---|---|
Severe akathisia as a side effect of metoclopramide.
Topics: Akathisia, Drug-Induced; Breast Neoplasms; Female; Humans; Metoclopramide; Middle Aged; Severity of | 2010 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
[Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
An audit of antiemetic use with CMF chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dex | 1998 |
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Canada; Cost-Benefit Analysis; Humans; Metoclo | 1999 |
Elevation of plasma prolactin in patients undergoing autologous blood stem-cell transplantation for breast cancer: is its modulation a step toward posttransplant immunotherapy?
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Confidence Intervals; Disease-Free Surv | 2000 |
Effects of synthetic gestagens on serum prolactin and growth hormone secretion in amenorrheic patients.
Topics: Amenorrhea; Breast Neoplasms; Female; Growth Hormone; Humans; Medroxyprogesterone; Metoclopramide; N | 1978 |
[Primperan and irradiation].
Topics: Breast Neoplasms; Cobalt Radioisotopes; Drug Evaluation; Female; Humans; Metoclopramide | 1976 |
[Intrapleural administration of CDDP against malignant pleural effusions in breast cancer].
Topics: Aged; Breast Neoplasms; Cisplatin; Female; Humans; Hydrocortisone; Infusions, Intravenous; Mastectom | 1990 |
[Mastopathy and breast cancer: is there a typical hormone profile?].
Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estrogens; Female; Fibrocystic Breast Disease; Follicle St | 1986 |
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1987 |
High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dex | 1986 |
Metoclopramide-induced phantom dyskinesia.
Topics: Amputation, Surgical; Breast Neoplasms; Dyskinesia, Drug-Induced; Female; Humans; Mastectomy; Metocl | 1985 |
Letter: Metaclopramide and prolactin.
Topics: Breast Neoplasms; Humans; Metoclopramide; Prochlorperazine; Prolactin | 1974 |
Letter: Metaclopramide and prolactin.
Topics: Breast Neoplasms; Female; Humans; Metoclopramide; Phenothiazines; Prolactin | 1974 |